We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Large-scale study will test GSK’s jab in 26,000 people in Africa and south-east Asia
The former head of the US defence department’s research agency was behind big bets on mRNA technology
Biggest biomedical charity makes first investment in science infrastructure from its endowment
Charity’s chair Julia Gillard commits to £16bn investment in science and health over next decade
Medical charity will introduce funding stream aimed at black and minority researchers
Philanthropist calls on governments to contribute billions to tackle future pathogens and increase vaccine supplies
Top UK medical charity to focus on next generation vaccines as it warns of complacency over future variants
Jeremy Farrar calls Covid-19 picture ‘concerning’ but insists he is not leaving Sage as a protest
Medical charity’s endowment boosted investments in research, much of it tied to pandemic
Medical charity commits to long-term investment in regeneration-focused housebuilding
The FT is working with the Wellcome Trust to raise awareness of a growing threat
US concerns that Trump will rush to approve a vaccine before election is playing into wider safety fears
The Wellcome Trust's Jeremy Farrar on the prospects for a Covid-19 vaccine
Former Australian prime minister will be first non-Briton to head UK’s biggest charity
Research group launches ‘Covid-zero’ to fund hunt for vaccines, treatments and testing
Accelerator fund will test whether existing drugs such as chloroquine can treat coronavirus
Research foundations join forces with Mastercard-backed charity to develop treatments
Mental wellbeing is a critical business issue and we should treat it as one
Wellcome study reveals ‘shocking portrait of research environment’
A big employer has cancelled plans to pilot shorter hours, citing business disruption
There is no viable path for new drugs, however valuable they are to society
Biotech companies need big pharma to bring innovative antibiotics to market
Merck collaboration for new generation of pills could be worth as much as $340m
Governments and scientists need to co-operate to educate the public
Charity will terminate £3.5m worth of grants to Nazneen Rahman
International Edition
